Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.37 |
| ▸ | FURIN | P09958 | 3/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | HPN | P05981 | 1/20 | 0.36 |
| ▸ | GLP1R | P43220 | 8/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14012359 | 0.96 | HTT (0.37) | HTTSIRT1SIRT2FURINPLAU | |
| SCHEMBL14012349 | 0.91 | TLR2 (0.41) | SIRT1SIRT2FURINGLP1RCA12 | |
| SCHEMBL13310984 | 0.88 | FAP (0.36) | HTTSIRT1SIRT2FURIN | |
| SCHEMBL13401426 | 0.87 | GLP1R (0.40) | FURINGLP1R | |
| SCHEMBL22138371 | 0.87 | FURIN (0.44) | HTTSIRT1SIRT2FURINGLP1R | |
| SCHEMBL10084803 | 0.86 | HTT (0.42) | HTTSIRT1SIRT2FURINPLAU | |
| SCHEMBL23429029 | 0.84 | HTT (0.41) | HTTFURINPLAUHPN | |
| SCHEMBL22138449 | 0.84 | SIRT1 (0.41) | HTTSIRT1SIRT2FURIN | |
| SCHEMBL24829575 | 0.84 | SIRT1 (0.41) | HTTSIRT1SIRT2FURIN | |
| SCHEMBL13401455 | 0.82 | GLP1R (0.38) | FURINGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | CD47, ANTXR2, CD2BP2 | HTT 1888/4885SIRT1 4116/4885SIRT2 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.